Modeling the impact of a long-term horizon and multiple treatment episodes on estimates of the cost-effectiveness of alcohol treatment in the United States

被引:2
|
作者
Barbosa, Carolina [1 ]
Dowd, William N. [1 ]
Karriker-Jaffe, Katherine J. [2 ,3 ]
Zarkin, Gary [1 ]
机构
[1] RTI Int, 3040 East Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA
[2] RTI Int, Berkeley, CA USA
[3] RTI Int, Behav Hlth Res Div, 2150 Shattuck Ave,Suite 800, Berkeley, CA 94704 USA
关键词
alcohol treatment; alcohol use disorder; cost-effectiveness analysis; drinking patterns; simulation modeling; USE DISORDERS; RISK DRINKING; CONSUMPTION; DEPENDENCE; HEALTH; COMBINE; PHARMACOTHERAPY; INTERVENTIONS; MORTALITY; OUTCOMES;
D O I
10.1111/acer.15186
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundMost clinical studies of alcohol use disorder (AUD) treatment have short follow-up periods, underestimating the full benefits of alcohol treatment. Furthermore, clinical studies only consider one treatment cycle and do not account for the need for multiple episodes to treat a chronic recurrent condition.MethodsA validated microsimulation model of the long-term drinking patterns of people with AUD in the United States simulated 10,000 individuals resembling those from a large clinical trial. The model was used to assess the impact of (1) 1-year, 5-year, and lifetime horizon on alcohol treatment cost-effectiveness estimates and (2) no, one, two, four, and unlimited additional treatment episodes on alcohol treatment cost-effectiveness estimates. Model outcomes included healthcare costs, crime costs, labor market productivity, life expectancy, quality-adjusted life years (QALYs), alcohol-related hospitalizations, and deaths. Cost-effectiveness analyses were conducted for two perspectives: a healthcare perspective that included costs from hospitalization and AUD treatment, and a broader societal perspective that also included crime costs and productivity.ResultsThe incremental cost per additional QALY gained for alcohol treatment compared with no treatment decreased from $55,590 after 1 year to $78 when healthcare costs and QALYs were tracked over the lifetime, that is, treatment became more cost effective. Treatment was cost saving for any time frame when the impacts on crime and labor productivity were also accounted for in a societal perspective. Access to multiple treatment episodes dominated (i.e., it was more effective and less costly) than no-treatment and one-episode scenarios. From a healthcare perspective, incremental costs per additional QALY for increasing from a maximum of two to four treatment episodes was $499 and from four to unlimited episodes was $5049. The unlimited treatment scenario dominated all others from a societal perspective. Results were robust in sensitivity analyses.ConclusionsA long-term perspective and multiple episodes of alcohol treatment improve cost-effectiveness estimates. When societal impacts are included, alcohol treatment is cost saving. Results support the value of alcohol treatment.
引用
收藏
页码:2121 / 2137
页数:17
相关论文
共 50 条
  • [1] Modeling the impact of a long-term horizon and multiple treatment episodes on the cost-effectiveness of alcohol treatment in the United States
    Barbosa, C.
    Dowd, W.
    Zarkin, G.
    Karriker-Jaffe, K.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 47 : 135 - 136
  • [2] MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES
    Wang, S. T.
    Huang, H.
    Shi, H.
    Duh, M. S.
    Chen, K.
    Chang, E.
    Korves, C.
    Dhawan, R.
    Cakana, A.
    Van de Velde, H.
    Esseltine, D. L.
    Garrison, L.
    VALUE IN HEALTH, 2010, 13 (03) : A210 - A210
  • [3] The long-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States.
    Dickens, T
    Raasch, RH
    Saal, GB
    Yeh, YC
    HEPATOLOGY, 2000, 32 (04) : 590A - 590A
  • [4] The cost-effectiveness of long-term post-treatment peer recovery support services in the United States
    de Martell, Sierra Castedo
    Moore, Margaret Brannon
    Wang, Hannah
    Steiker, Lori Holleran
    Wilkerson, J. Michael
    Ranjit, Nalini
    Mccurdy, Sheryl A.
    Brown, H. Shelton
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2025,
  • [5] Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States
    Pan, Feng
    Goh, Jo Wern
    Cutter, Gary
    Su, Wayne
    Pleimes, Dirk
    Wang, Cheng
    CLINICAL THERAPEUTICS, 2012, 34 (09) : 1966 - 1976
  • [6] LONG-TERM COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA IN THE UNITED STATES
    Rajagopalan, K.
    O'Day, K.
    Meyer, K.
    Pikalov, A. A., III
    Loebel, A.
    VALUE IN HEALTH, 2012, 15 (04) : A87 - A87
  • [7] Estimating the long-term cost-effectiveness of exenatide in the United States: An adjunctive treatment for type 2 diabetes mellitus
    Minshall, Michael E.
    Oglesby, Alan K.
    Wintle, Matthew E.
    Valentine, William J.
    Roze, Stephane
    Palmer, Andrew J.
    VALUE IN HEALTH, 2008, 11 (01) : 22 - 33
  • [8] Long-term cost-effectiveness analysis of early treatment with IFNB-1b among multiple sclerosis patients in the United States
    Pan, F.
    Goh, J.
    Cutter, G.
    Wang, C.
    Su, W.
    Knappertz, V.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S96 - S97
  • [9] The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States
    Wang, Si-Tien
    Huang, Hui
    Shi, Hongliang
    Duh, Mei Sheng
    Chen, Ktistina
    Chang, Eva
    Korves, Caroline
    Dhawan, Ravinder
    Cakana, Andrew
    van de Velde, Helgi
    Esseltine, Dixie-Lee
    Garrison, Louis
    BLOOD, 2009, 114 (22) : 561 - 562
  • [10] Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C
    Sroczynski, G.
    Esteban, E.
    Conrads-Frank, A.
    Schwarzer, R.
    Muehlberger, N.
    Wright, D.
    Zeuzem, S.
    Siebert, U.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 (01) : 34 - 50